A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Inclusion Criteria:

Pediatric patients aged 3 months to less than 12 years at the time of Pradaxa Pellets initiation

• Written informed consent from parents/care givers and patient assent if ageappropriate

• Initiation of Pradaxa Pellets administration either as initial or subsequenttherapy:

• Treatment of VTE

• Treatment to reduce the risk of recurrence of VTE

Exclusion Criteria:

• Participation in any randomized clinical trial or use of investigational product,participation in any other observational study is not an exclusion

• Any contraindications to Pradaxa Pellets according to the US PrescribingInformation.

• Previous participation in this study.